Distal motor latency and residual latency as sensitive markers of anti-MAG polyneuropathy

Journal of Neurology

Volumn 250, Issue 8, 2003, Pages 962-966

  Radziwill, Alexander J ^a,b,c   Steck, Andreas J ^b   Renaud, Susanne ^b   Fuhr, Peter ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c NONE   (Switzerland)

Author keywords

Anti myelin associated glycoprotein polyneuropathy; Chronic inflammatory demyelinating polyneuropathy; Distal motor latency; Residual latency; Terminal latency index

Indexed keywords

ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN ASSOCIATED GLYCOPROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ADULT; AGED; ARTICLE; AXILLA; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE MARKER; DISTAL MOTOR LATENCY; ELBOW; ELECTRONEUROGRAPHY; HUMAN; HUMAN TISSUE; HYPOTHESIS; MOTOR NERVE CONDUCTION; NERVE BIOPSY; PARAMETER; PRIORITY JOURNAL; RESIDUAL LATENCY; STATISTICAL SIGNIFICANCE; TERMINAL LATENCY INDEX; ULNAR NERVE; WRIST;

ACTION POTENTIALS; ADULT; AGED; ANTIBODIES; BIOLOGICAL MARKERS; ELBOW; ELECTROPHYSIOLOGY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MIDDLE AGED; MYELIN-ASSOCIATED GLYCOPROTEIN; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; REACTION TIME; REVIEW LITERATURE; ULNAR NERVE; WRIST;

EID: 0042882815     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-1128-7     Document Type: Article

References (17)

1. Attarian S, Azulay JP, Boucraut J, Escande N, Pouget J (2001) Terminal latency index and modified F ration in distinction of chronic demyelinating neuropathies. Clin Neurophysiol 112:457-463
2. Cocito D, Isoardo G, Ciaramitaro P, Migliaretti G, Pipieri A, Barbero P, Cucci A, and Durelli L (2001) Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody. Muscle Nerve 24:1278-1282
3. Cornblath DR, Asbury AK, Albers JW, Feasby TE, Hahn AF, McLeod JG, Mendell JR, Parry GJ, Pollard JD, Thomas PK (1991) Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41:616-618
4. Creange A, Lefaucheur JP, Authier FJ, Gherardi RK (1998) Cytokines and peripheral neuropathies. Rev Neurol (Paris) 154:208-216
5. Daube JR (1996) Compound muscle action potentials. In: Daube JR (ed) Clinical Neurophysiology. FA Davis Company, Philadelphia, pp 199-324
6. Dyck PJ, Dyck PJ (2000) Atypical varieties of chronic inflammatory demyelinating neuropathies. Lancet 355(9212):1293-1294
7. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV (1998) Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 44:780-788
8. Kaku DA, England JD, Sumner AJ (1994) Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl-paragloboside. Brain 117:941-947
9. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ (2000) Distal acquired demyelinating symmetric neuropathy. Neurology 54:615-620
10. Melendez-Vasquez C, Redford J, Choudhary PP, Gray IA, Maitland P, Gregson NA, Smith KJ, Hughes RA (1997) Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 73:124-134
11. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G (2000) Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 123:710-717
12. Radziwill AJ, Kuntzer T, Steck AJ (2002) Immunopathology and treatment of Guillain-Barré syndrome and of chronic inflammatory demyelinating polyneuropathy. Rev Neurol (Paris) 158:301-310
13. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A, Steck AJ (2001) Rituximab and anti-MAG-associated polyneuropathy: A pilot study. Neurology 56(8):A396-A396 (Suppl. 3)
14. Rizzuto N, Morbin M, Cavallaro T, Ferrari S, Fallahi M, Galiazzo-Rizzuto S (1998) Focal lesions area feature of chronic inflammatory demyelinating polyneuropathy (CIDP). Acta Neuropathol (Berl) 96:603-609
15. Shahani BT, Young RR, Potts F, Maccabee P (1979) Terminal latency index (TLI) and late response studies in motor neuron disease (MND), peripheral neuropathies and entrapment syndromes (abstract). Acta Neurol Scand (Supp. 73):118
16. Steck AJ, Murray N, Meier C, Page N, Perruisseau G (1983) Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein. Neurology 33:19-23
17. Trojaborg W, Hays AP, Vandenberg L, Younger DS, Latov N (1995) Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies. Muscle Nerve 18:730-735